Swissmedic approves Paxlovid for COVID-19 patients

17 juin 2022 – Swissmedic has authorised Paxlovid, which could already be prescribed in Switzerland based on the Covid-19 Ordinance 3, for a limited period of two years. It is taken in tablet form and can be used to treat Covid-19. Swissmedic reviewed the marketing authorisation application from 14 January 2022 as part of a rolling assessment. In the process, the required data were continuously collected and submitted against the Omikron variants. However, the laboratory data indicate that Paxlovid is effective against the Omikron variants in vitro.

For more information, see here.